Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Free Cash Flow (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Free Cash Flow for 4 consecutive years, with -$25.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 9.01% to -$25.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$113.0 million, a 0.8% increase, with the full-year FY2024 number at -$110.3 million, down 8.04% from a year prior.
  • Free Cash Flow was -$25.8 million for Q3 2025 at Century Therapeutics, up from -$27.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $83.0 million in Q1 2022 to a low of -$52.3 million in Q4 2022.
  • A 4-year average of -$21.2 million and a median of -$27.8 million in 2023 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 47.95% in 2023; the steepest drop was 136.4% in 2023.
  • Century Therapeutics' Free Cash Flow stood at -$52.3 million in 2022, then surged by 47.95% to -$27.2 million in 2023, then increased by 10.98% to -$24.2 million in 2024, then decreased by 6.42% to -$25.8 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Free Cash Flow are -$25.8 million (Q3 2025), -$27.9 million (Q2 2025), and -$35.1 million (Q1 2025).